Birgit Knoechel

Hematology | Oncology
450 Brookline Ave
Boston, MA 02215

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications

Altered immune and treatment response gene expression signatures among poverty-exposed children with B-ALL.

Altered immune and treatment response gene expression signatures among poverty-exposed children with B-ALL.

Journal: bioRxiv : the preprint server for biology
Published: February 09, 2026

Altered immune and treatment response gene expression signatures among povertyexposed children with B-cell acute lymphoblastic leukemia.

Altered immune and treatment response gene expression signatures among povertyexposed children with B-cell acute lymphoblastic leukemia.

Journal: Haematologica
Published: October 07, 2025

Self-Assembling Multi-Antigen T Cell Hybridizers for Precision Immunotherapy of Multiple Myeloma.

Self-Assembling Multi-Antigen T Cell Hybridizers for Precision Immunotherapy of Multiple Myeloma.

Journal: Advanced healthcare materials
Published: May 27, 2025

Cell-free DNA as a complementary marker of therapeutic futility in adenoid cystic carcinoma.

Cell-free DNA as a complementary marker of therapeutic futility in adenoid cystic carcinoma.

Journal: Oral oncology
Published: April 15, 2025

Genome-wide CRISPR screen identifies IRF1 and TFAP4 as transcriptional regulators of Galectin-9 in T cell acute lymphoblastic leukemia.

Genome-wide CRISPR screen identifies IRF1 and TFAP4 as transcriptional regulators of Galectin-9 in T cell acute lymphoblastic leukemia.

Journal: Science advances
Published: March 19, 2025

The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma.

The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma.

Journal: Leukemia
Published: November 26, 2024

Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma.

Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma.

Journal: Blood advances
Published: November 07, 2024

Combining MCL-1 inhibition and CD37-directed chimeric antigen receptor T cells as an effective strategy to target T-cell lymphoma.

Combining MCL-1 inhibition and CD37-directed chimeric antigen receptor T cells as an effective strategy to target T-cell lymphoma.

Journal: Leukemia
Published: October 08, 2024

Remodeling of the immune microenvironment is linked to adverse outcome in pediatric T cell acute lymphoblastic leukemia.

Remodeling of the immune microenvironment is linked to adverse outcome in pediatric T cell acute lymphoblastic leukemia.

Journal: Nature communications
Published: September 25, 2024

Dual role of signaling pathways in myeloma requires cell type-specific targeting of ligand-receptor interactions.

Dual role of signaling pathways in myeloma requires cell type-specific targeting of ligand-receptor interactions.

Journal: Blood advances
Published: August 17, 2023

Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering.

Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering.

Journal: Science advances
Published: July 26, 2023

Identification of an Epi-metabolic dependency on EHMT2/G9a in T-cell acute lymphoblastic leukemia.

Identification of an Epi-metabolic dependency on EHMT2/G9a in T-cell acute lymphoblastic leukemia.

Journal: Cell death & disease
Published: January 25, 2022
Showing 1-12 of 36

Last Updated: 09/26/2026